Laura Blair: Balancing Virtual Fulfillment and Traditional Pharmacy Distribution

The pharmaceutical commercialization landscape is undergoing a significant transformation, driven by innovative therapy classes and a fundamental shift in how manufacturers engage with the end user. As direct-to-patient (DTP) models and virtual fulfillment continue to gain traction, the industry is moving beyond traditional distribution to create more personalized, transparent pathways for medication access.

In the first part of her video interview with Pharmaceutical Commerce, Laura Blair, chief commercial officer at ConnectiveRx, discusses the evolution of patient access strategies and the "ground shift" triggered by the rise of GLP-1s. Blair explores the nuances of DTP models, emphasizing that while many associate the term with simple cash-pay options, the true value lies in proactive "conversations" with patients. This involves integrated benefits verification to determine whether a commercial, government, or cash-pay route offers the best long-term outcome for a patient's specific clinical and financial situation.

Blair also highlights the importance of flexibility in fulfillment, balancing the convenience of home delivery with the continued relevance of local pharmacy networks. By applying consumer-level transparency to complex therapies—ranging from weight loss to oncolytics and chronic disease medications—manufacturers can better navigate the "homework" of benefit design to ensure patients remain adherent to their treatment journeys.